发明名称 |
BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND EVEROLIMUS |
摘要 |
Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is in need of a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma. |
申请公布号 |
WO2016194348(A1) |
申请公布日期 |
2016.12.08 |
申请号 |
WO2016JP02562 |
申请日期 |
2016.05.27 |
申请人 |
EISAI R&D MANAGEMENT CO., LTD. |
发明人 |
FUNAHASHI, Yasuhiro;KADOWAKI, Tadashi |
分类号 |
G01N33/574 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|